Exodus Point Capital Management, LP Ligand Pharmaceuticals Inc Transaction History

Exodus Point Capital Management, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$58.86 - $72.67 $381,000 - $470,392	6,473 Added 30.38%	27,783 $1.67 Million
Q2 2023 Aug 10, 2023	BUY	$69.53 - $79.33 $1.48 Million - $1.69 Million	21,310 New	21,310 $1.54 Million
Q4 2022 Feb 13, 2023	BUY	$61.72 - $96.74 $766,624 - $1.2 Million	12,421 Added 220.15%	18,063 $1.21 Million
Q3 2022 Nov 10, 2022	BUY	$0.01 - $107.56 $56 - $606,853	5,642 New	5,642 $486,000
Q2 2021 Aug 16, 2021	SELL	$113.03 - $155.64 $259,969 - $357,971	-2,300 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$99.52 - $215.83 $384,644 - $834,182	-3,865 Reduced 62.69%	2,300 $351,000
Q4 2020 Feb 16, 2021	BUY	$80.55 - $106.05 $229,809 - $302,560	2,853 Added 86.14%	6,165 $613,000
Q3 2020 Nov 16, 2020	SELL	$89.56 - $126.72 $576,676 - $815,950	-6,439 Reduced 66.03%	3,312 $316,000
Q2 2020 Aug 14, 2020	BUY	$68.28 - $123.65 $665,798 - $1.21 Million	9,751 New	9,751 $1.09 Million

249

17.7M

61K

7.8K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.91B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.